Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Harnessing AI to optimize the development of new protein manufacturing processes

Industrial yeasts are a powerhouse of protein production, used to manufacture vaccines, biopharmaceuticals, and other useful compounds.

17 Feb 2026

Fred Hutch scientists reach crucial milestone in blocking Epstein Barr virus

Fred Hutch Cancer Center scientists reached a crucial milestone in blocking Epstein Barr virus (EBV), a pathogen estimated to infect 95% of the global population that is linked to multiple types of cancer, neurodegenerative diseases and other chronic health conditions.

17 Feb 2026

Chronic inflammation shapes cancer progression and immunotherapy response

Chronic inflammation is both a driver and suppressor of cancer depending on context. Key players-NF-κB, IL-6, STAT3, TAMs, MDSCs, and Tregs-orchestrate a tumor-permissive microenvironment.

16 Feb 2026

Nasal COVID vaccine boost increases IgA responses linked to variant neutralisation

Intranasal boosting after prior intramuscular COVID vaccination induced strong mucosal IgA responses in a small human cohort. These antibodies showed markedly enhanced neutralising activity against Omicron variants and evidence of immune memory reprogramming toward mucosal protection.

15 Feb 2026

Antibody feedback reshapes B cell selection during immune response

A collaborative study published in Immunity from the Batista Lab and Liu Lab at the Ragon Institute, together with the Schief Lab at Scripps Research Institute, has uncovered a previously unrecognized mechanism that shapes how immune cells are selected during an immune response.

13 Feb 2026

Novel antibody 007 targets the elusive HIV envelope epitope

HIV-1 can be neutralized by antibodies which bind to vulnerable structures on the virus surface. One such vulnerable site is the so-called V3 glycan site of the viral envelope protein.

13 Feb 2026

New AI framework enables reliable intracellular antibody design

A new artificial intelligence-driven pipeline developed in a collaborative research combines protein structure prediction, sequence design, and live-cell screening together to enable rapid conversion of antibody sequences into functional intracellular antibodies (intrabodies) that are stable within living cells.

13 Feb 2026

Case report examines potential cancer risks after mRNA vaccination

A new case report was published in Volume 17 of Oncotarget on February 6, 2026, titled "Exploring the potential link between mRNA COVID-19 vaccinations and cancer: A case report with a review of haematopoietic malignancies with insights into pathogenic mechanisms."

12 Feb 2026

Trial highlights promising frontline therapy for blastic plasmacytoid dendritic cell neoplasm

Seventy-five percent of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) who were treated with the antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) had a complete response, according to new data from the Phase I/II multicenter international CADENZA trial led by researchers at The University of Texas MD Anderson Cancer Center.

11 Feb 2026

Study uncovers immune trigger behind vaccine-induced immune thrombocytopenia and thrombosis

A global research collaboration of scientists from McMaster University (Canada), Flinders University (Australia) and Universitätsmedizin Greifswald (Germany) uncovered why a small number of people developed dangerous blood clots after either receiving certain COVID‑19 vaccines or experiencing a natural adenovirus infection, and the answer lies in an unexpected case of misdirected targeting by the immune system.

11 Feb 2026

Alzheimer’s plaques decline after CAR-T immune cell treatment in preclinical study

Researchers engineered CD4+ chimeric antigen receptor T cells targeting fibrillar amyloid beta and tested them in a mouse Alzheimer model. The preclinical study showed reduced amyloid pathology and altered neuroimmune responses, supporting CAR-T immunotherapy as a potential future Alzheimer strategy.

11 Feb 2026

Preexisting flu immunity may offer baseline protection against avian influenza

Are seasonal flu antibodies also effective against avian flu? A team from the University of Geneva (UNIGE) has shown that a specific type of antibody associated with the former virus—already present throughout the population—may offer baseline protection against the latter.

10 Feb 2026

AI model accelerates antibody production and clone selection

As instigators of immunity, monoclonal antibodies are marvels of modern medicine, lab-made proteins that can treat cancers, autoimmune diseases, and many other conditions.

9 Feb 2026

New DNA-based vaccine scaffolds boost targeted immune responses to HIV

One of the biggest hurdles in developing an HIV vaccine is coaxing the body to produce the right kind of immune cells and antibodies. In most vaccines, HIV proteins are attached to a larger protein scaffolding that mimics a virus.

6 Feb 2026

Inhibiting PTP1B protein improves memory in Alzheimer’s disease models

Alzheimer's disease is often measured in statistics: millions affected worldwide, cases rising sharply, costs climbing into the trillions.

5 Feb 2026

Study reveals evidence of silent mpox exposure in healthy Nigerians

New evidence suggests that mpox may be circulating quietly among healthy Nigerians, with some infections occurring without the symptoms that typically trigger detection by health authorities.

5 Feb 2026

Gut microbial butyrate enhances mucosal vaccine antibody responses

A research team from POSTECH and ImmunoBiome in Korea, led by Professor Sin-Hyeog Im, has uncovered a new mechanism showing how butyrate-a short-chain fatty acid produced by gut commensal bacteria-enhances T follicular helper (Tfh) cell activity to promote antibody production and strengthen mucosal vaccine efficacy.

4 Feb 2026

Why did influenza fail to spread in a crowded indoor setting?

The EMIT-2 trial shows zero influenza transmission despite ideal conditions, suggesting a perfect storm is needed for the virus to spread effectively.

4 Feb 2026

Australian researchers develop a new way to target deadly, drug-resistant bacteria

Australian researchers have developed a powerful new way to target deadly, drug-resistant bacteria by designing antibodies that recognize a sugar found only on bacterial cells – an advance that could underpin a new generation of immunotherapies for multidrug resistant hospital-acquired infections.

4 Feb 2026

Overlooked animal viruses slipping past global disease surveillance

The study on Influenza D and Canine Coronavirus HuPn-2018 underscores urgent needs for targeted surveillance and diagnostics in infectious disease research.

2 Feb 2026